Press release
Alzheimer's Disease Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Therapies, and Companies by DelveInsight | Neurodon, Sangamo Therapeutics, NKGen Biotech, Asceneuron, TrueBinding, Alector, Cognition Therapeutics, Anavex Life Science
Alzheimer's Disease Clinical Trials
The Alzheimer's Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
"Alzheimer's Disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Alzheimer's Disease Market.
Some of the key takeaways from the Alzheimer's Disease Pipeline Report:
https://www.delveinsight.com/sample-request/alzheimers-disease-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
• Companies across the globe are diligently working toward developing novel Alzheimer's Disease treatment therapies with a considerable amount of success over the years.
• Alzheimer's Disease companies working in the treatment market are Neurodon, Sangamo Therapeutics, NKGen Biotech, Asceneuron, TrueBinding, Alector, Cognition Therapeutics, Anavex Life Sciences, Eisai Co Ltd, Cassava Sciences, Inc., Karuna Therapeutics, BioVie, and others, are developing therapies for the Alzheimer's Disease treatment
• Emerging Alzheimer's Disease therapies in the different phases of clinical trials are- NRDN-201, ST-501, SNK 01, ASN51, TB 006, AL002, CT-1812, Blarcamesine, E 2814, Simufilam, KarXT, NE3107, and others are expected to have a significant impact on the Alzheimer's Disease market in the coming years.
• In March 2024, MapLight Therapeutics, a clinical-stage biopharmaceutical company focused on developing targeted novel treatments for debilitating CNS disorders, announced the start of a Phase 1 clinical trial for ML-007/PAC. This is an extended-release fixed-dose combination of the novel investigational muscarinic agonist ML-007 and a precision-matched peripherally active anticholinergic (PAC). The trial builds on findings from three previous Phase 1 trials that assessed the safety and tolerability of ML-007 with PAC. The data from this new trial will guide the dosing regimen for upcoming Phase 2 trials targeting schizophrenia and Alzheimer's disease psychosis. The company plans to start its first Phase 2 trial of ML-007/PAC in schizophrenia later this year.
• In January 2024, AmyriAD Therapeutics plans to assess its leading Alzheimer's disease small molecule candidate, AD-101, in three forthcoming Phase III studies.
• In July 2023, Following a conclusion that a confirmatory trial demonstrated clinical benefit, the U.S. Food and Drug Administration converted Leqembi (lecanemab-irmb), intended to treat adult patients with Alzheimer's Disease, to conventional approval. Leqembi is the first amyloid beta-directed antibody for the treatment of Alzheimer's disease to transition from an accelerated approval to a conventional approval.
Alzheimer's Disease Overview
Alzheimer's disease is a progressive neurodegenerative disorder that primarily affects older adults, leading to cognitive decline, memory loss, and changes in behavior and personality. It is the most common cause of dementia, accounting for 60-80% of dementia cases.
Get a Free Sample PDF Report to know more about Alzheimer's Disease Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/alzheimers-disease-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Emerging Alzheimer's Disease Drugs Under Different Phases of Clinical Development Include:
• NRDN-201: Neurodon
• ST-501: Sangamo Therapeutics
• SNK 01: NKGen Biotech
• ASN51: Asceneuron
• TB 006: TrueBinding
• AL002: Alector
• CT-1812: Cognition Therapeutics
• Blarcamesine: Anavex Life Sciences
• E 2814: Eisai Co Ltd
• Simufilam: Cassava Sciences, Inc.
• KarXT: Karuna Therapeutics
• NE3107: BioVie
Alzheimer's Disease Route of Administration
Alzheimer's Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Alzheimer's Disease Molecule Type
Alzheimer's Disease Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Alzheimer's Disease Pipeline Therapeutics Assessment
• Alzheimer's Disease Assessment by Product Type
• Alzheimer's Disease By Stage and Product Type
• Alzheimer's Disease Assessment by Route of Administration
• Alzheimer's Disease By Stage and Route of Administration
• Alzheimer's Disease Assessment by Molecule Type
• Alzheimer's Disease by Stage and Molecule Type
DelveInsight's Alzheimer's Disease Report covers around 120+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Alzheimer's Disease product details are provided in the report. Download the Alzheimer's Disease pipeline report to learn more about the emerging Alzheimer's Disease therapies
https://www.delveinsight.com/sample-request/alzheimers-disease-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the key companies in the Alzheimer's Disease Therapeutics Market include:
Key companies developing therapies for Alzheimer's Disease are - AbbVie, Inc., Teva Pharmaceuticals Ltd., Eisai Co., Ltd., Janssen Pharmaceuticals, Inc., Johnson & Johnson, Novartis AG, Zydus Lifesciences Ltd (CADILA), Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd, Aurobindo Pharma Ltd, Amneal Pharmaceuticals Inc., Macleods Pharmaceuticals Ltd., Viatris Inc., Lupin Ltd, Cipla Ltd., Torrent Pharmaceuticals Ltd., Unichem laboratories ltd, Lannett Inc., and others.
Alzheimer's Disease Pipeline Analysis:
The Alzheimer's Disease pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Alzheimer's Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Alzheimer's Disease Treatment.
• Alzheimer's Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Alzheimer's Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Alzheimer's Disease market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Alzheimer's Disease drugs and therapies
https://www.delveinsight.com/sample-request/alzheimers-disease-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Alzheimer's Disease Pipeline Market Drivers
• Increase in prevalence of Alzheimer's Disease (AD), rising geriatric population are some of the important factors that are fueling the Alzheimer's Disease Market.
Alzheimer's Disease Pipeline Market Barriers
• However, clinical trials are more complicated, costly, and slower than trials for other diseases., lack of clear diagnosis and other factors are creating obstacles in the Alzheimer's Disease Market growth.
Scope of Alzheimer's Disease Pipeline Drug Insight
• Coverage: Global
• Key Alzheimer's Disease Companies: Neurodon, Sangamo Therapeutics, NKGen Biotech, Asceneuron, TrueBinding, Alector, Cognition Therapeutics, Anavex Life Sciences, Eisai Co Ltd, Cassava Sciences, Inc., Karuna Therapeutics, BioVie, and others
• Key Alzheimer's Disease Therapies: NRDN-201, ST-501, SNK 01, ASN51, TB 006, AL002, CT-1812, Blarcamesine, E 2814, Simufilam, KarXT, NE3107, and others
• Alzheimer's Disease Therapeutic Assessment: Alzheimer's Disease current marketed and Alzheimer's Disease emerging therapies
• Alzheimer's Disease Market Dynamics: Alzheimer's Disease market drivers and Alzheimer's Disease market barriers
Request for Sample PDF Report for Alzheimer's Disease Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/alzheimers-disease-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Contents
1. Alzheimer's Disease Report Introduction
2. Alzheimer's Disease Executive Summary
3. Alzheimer's Disease Overview
4. Alzheimer's Disease- Analytical Perspective In-depth Commercial Assessment
5. Alzheimer's Disease Pipeline Therapeutics
6. Alzheimer's Disease Late Stage Products (Phase II/III)
7. Alzheimer's Disease Mid Stage Products (Phase II)
8. Alzheimer's Disease Early Stage Products (Phase I)
9. Alzheimer's Disease Preclinical Stage Products
10. Alzheimer's Disease Therapeutics Assessment
11. Alzheimer's Disease Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Alzheimer's Disease Key Companies
14. Alzheimer's Disease Key Products
15. Alzheimer's Disease Unmet Needs
16 . Alzheimer's Disease Market Drivers and Barriers
17. Alzheimer's Disease Future Perspectives and Conclusion
18. Alzheimer's Disease Analyst Views
19. Appendix
20. About DelveInsight
Trending Reports:
• Bladder Cancer Market: https://www.delveinsight.com/report-store/bladder-cancer-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Cardiac Biomarkers Testing Devices Market: https://www.delveinsight.com/report-store/cardiac-biomarkers-testing-devices-market
• Central Venous Catheters Market: https://www.delveinsight.com/report-store/central-venous-catheters-market
• Epilepsy Market: https://www.delveinsight.com/report-store/epilepsy-market
• Gaucher Disease Market: https://www.delveinsight.com/report-store/gauchers-disease-market
• Generalized Pustular Psoriasis Market: https://www.delveinsight.com/report-store/generalized-pustular-psoriasis-market
• Healthcare Due Diligence Services: https://www.delveinsight.com/consulting/due-diligence-services
• Hemodynamic Monitoring Systems Market: https://www.delveinsight.com/report-store/hemodynamic-monitoring-system-market
• Implantable Infusion Pumps Market: https://www.delveinsight.com/report-store/implantable-infusion-pumps-market
• Neuromodulation Devices Market: https://www.delveinsight.com/report-store/neuromodulation-devices-market
• Neurostimulation Devices Market: https://www.delveinsight.com/report-store/neurostimulation-devices-market
• Neurotrophic Keratitis Market: https://www.delveinsight.com/report-store/neurotrophic-keratitis-market
• Post Traumatic Stress Disorder Market: https://www.delveinsight.com/report-store/post-traumatic-stress-disorder-ptsd-market
• Post-bariatric Hypoglycemia Market: https://www.delveinsight.com/report-store/post-bariatric-hypoglycemia-market
• Absssi Market: https://www.delveinsight.com/report-store/acute-bacterial-skin-and-skin-structure-infections-market
• Acute Gout Flare Market: https://www.delveinsight.com/report-store/acute-gout-flare-market
• Adrenoleukodystrophy Market: https://www.delveinsight.com/report-store/adrenoleukodystrophy-market
• Adult Myopia Market: https://www.delveinsight.com/infographics/adult-myopia-market
• Alopecia Areata Market: https://www.delveinsight.com/report-store/alopecia-areata-market
• Alpha-mannosidosis Market: https://www.delveinsight.com/report-store/alpha-mannosidosis-market
• Androgenetic Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
• Anemia In Ckd Market: https://www.delveinsight.com/report-store/anemia-in-chronic-kidney-disease-market
• Anterior Cruciate Ligament Injuries Market: https://www.delveinsight.com/report-store/anterior-cruciate-ligament-injuries-market
• Artificial Lung Devices Market: https://www.delveinsight.com/report-store/artificial-lung-devices-pipeline-insight-and-competitive-landscape
• Automated External Defibrillators Market: https://www.delveinsight.com/report-store/automated-external-defibrillator-aed-market
• Biochips Market: https://www.delveinsight.com/blog/biochips-market-landscape
• Cardiac Amyloidosis Market: https://www.delveinsight.com/report-store/cardiac-amyloidosis-market
• Carpal Tunnel Syndrome Market: https://www.delveinsight.com/report-store/carpal-tunnel-release-system-market
• Centronuclear Myopathy Market: https://www.delveinsight.com/report-store/centronuclear-myopathy-cnm-pipeline-insight
• Chronic Rhinosinustis Market: https://www.delveinsight.com/report-store/chronic-rhinosinusitis-with-nasal-polyps-market
• Competitive Intelligence Pharma: https://www.delveinsight.com/blog/competitive-intelligence-in-healthcare-sector
• Concussions Market Size: https://www.delveinsight.com/report-store/concussions-market
• Cutaneous T Cell Lymphoma Market: https://www.delveinsight.com/infographics/cutaneous-t-cell-lymphoma-ctcl-market
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/conference-coverage-services
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Alzheimer's Disease Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Therapies, and Companies by DelveInsight | Neurodon, Sangamo Therapeutics, NKGen Biotech, Asceneuron, TrueBinding, Alector, Cognition Therapeutics, Anavex Life Science here
News-ID: 3677530 • Views: …
More Releases from DelveInsight Business Research
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals.
Objective of the Case Study
The…
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics.
According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than…
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies.
Biopsy devices play a crucial role in disease diagnosis by…
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide.
DelveInsight's General Surgery Devices Market Report 2032 provides…
More Releases for Alzheimer
Dementia - Alzheimer Disease Market: A Comprehensive Analysis 2030
Dementia and Alzheimer's disease represent significant challenges within the global healthcare sector. These neurological disorders, characterized by progressive cognitive decline, have seen increasing prevalence due to aging populations worldwide. This growing burden has spurred interest in the Dementia - Alzheimer's disease market, encompassing diagnostic tools, treatments, caregiving solutions, and related healthcare services. This article provides an overview of the market, its scope, current trends, and factors driving its expansion.
Data Bridge…
Alzheimer Disease Treatment Market | Allergan, Amgen, Daiichi Sankyo, Eisai
The global alzheimer disease treatment market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the alzheimer disease treatment market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth…
United States Alzheimer Drugs Market Insights Deep Analysis 2023-2031
Cognate Life Sciences introduces a report on "United States Alzheimer Drugs Market 2023" with Market Insights Reports, Introduces systematic details in terms of market valuation, market size, revenue estimation, and geographical spectrum of the business vertical. The study also talks about crucial pockets of the industry such as products or services offered, downstream fields, end using customers, historic data figures regarding revenue and sales, market context and more. It conjointly…
Global Alzheimer Market, Global Alzheimer Industry, Covid-19 Impact Global Alzhe …
Alzheimer's is a progressive disease that leads to the death of brain cells, resulting in memory loss, behavioral issues, and disruption the thought processes. The Alzheimer disease is considered fatal. Age and heredity are the two main risk factors for developing Alzheimer's disease. Several other preventable risk factors have been associated to the development of this disease, including diet, environment, and overall general health. A combination of risk factors is…
US Alzheimer Drug Pipeline Analysis
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this,…
Global Alzheimer Market Report: 2015 Edition | Now Available at Researchmoz.us
Researchmoz added Most up-to-date research on "Global Alzheimer Market Report: 2015 Edition" to its huge collection of research reports.
Alzheimer’s disease is defined as an advanced neurological disorder that increasingly deprives patients of their memory and ability to carry out daily activities. As it grows in a human brain, individuals are likely to practice difficulties in linguistic, agility and insight along with negative changes in the character and performance such as…
